Publications by authors named "Michael A Davies"

100Publications

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma.

Acta Derm Venereol 2020 Sep 28. Epub 2020 Sep 28.

Oncology-Pathology and Department of Oncology/Skin Cancer Center, Theme Cancer, Karolinska Institutet, Karolinska University Hospital Solna, SE-176 76 Stockholm, Sweden. E-mail:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3648DOI Listing
September 2020

Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report.

Immunotherapy 2020 Sep 9. Epub 2020 Sep 9.

Department of Translational & Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2020-0108DOI Listing
September 2020

Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.

J Invest Dermatol 2020 May 7. Epub 2020 May 7.

Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2020.02.047DOI Listing
May 2020

Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?

Authors:
Michael A Davies

J Clin Oncol 2020 May 25;38(15):1645-1647. Epub 2020 Feb 25.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00136DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238487PMC
May 2020

FOXD3 Regulates VISTA Expression in Melanoma.

Cell Rep 2020 01;30(2):510-524.e6

Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.12.036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995351PMC
January 2020

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

N Engl J Med 2019 08 4;381(7):626-636. Epub 2019 Jun 4.

From Institut Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Aix-Marseille University, Marseille (J.J.G.), and Assistance Publique-Hôpitaux de Paris Dermatology and Clinical Investigation Center, Unité 976, Université de Paris, Hôpital Saint-Louis, Paris (C.L.) - all in France; Moscow City Oncology Hospital, Moscow (D. Stroyakovskiy), and the Petrov Research Institute of Oncology, St. Petersburg (E.L.) - both in Russia; Przychodnia Lekarska Komed, Konin (B.K.), the University of Medical Sciences, Poznań (A.M.), and the Maria Skłodowska-Curie Institute-Oncology Center, Warsaw (P.R.) - all in Poland; the University Hospital Schleswig-Holstein, Kiel (A.H.), the Department of Dermatology, University of Tübingen, Tübingen (C.G.), University Hospital Essen, Essen (D. Schadendorf), and the German Cancer Consortium, Heidelberg (D. Schadendorf) - all in Germany; the Veneto Institute of Oncology, Padua (V.C.S.), and Papa Giovanni XXIII Hospital, Bergamo (M.M.) - both in Italy; the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer (J.S.), and Sackler Medical School, Tel Aviv University, Tel Aviv (J.S.) - both in Israel; Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine (I.B.); Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens (H.G.); the Netherlands Cancer Institute, Amsterdam (J.B.A.G.H.); Mount Vernon Cancer Centre, Northwood, United Kingdom (P.D.N.); the University of California, Los Angeles, Los Angeles (A.R.); the University of Texas M.D. Anderson Cancer Center, Houston (M.A.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (K.T.F.); Novartis Pharma, Basel, Switzerland (P.B.); Novartis Pharmaceuticals, East Hanover, NJ (M.T., E.G., M.V.); and the Melanoma Institute Australia, the University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1904059DOI Listing
August 2019

Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:e59-e69. Epub 2019 May 17.

4 Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_241345DOI Listing
January 2019

Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

J Neurooncol 2019 May 7;142(3):499-509. Epub 2019 Mar 7.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-019-03121-2DOI Listing
May 2019

Reply to A. Shinde et al.

J Clin Oncol 2019 04 26;37(12):1031-1032. Epub 2019 Feb 26.

Harriet M. Kluger, MD, Yale School of Medicine, New Haven, CT; Kim A. Margolin, MD, City of Hope, Duarte, CA; Michael A. Davies, MD, PhD, MD Anderson Cancer Center, Houston, TX; Georgina V. Long, PhD, The University of Sydney, Sydney, NSW, Australia; Hussein A. Tawbi, MD, PhD, MD Anderson Cancer Center, Houston, TX; and Sarah B. Goldberg, MD and Veronica L. Chiang, MD, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.02463
Publisher Site
http://dx.doi.org/10.1200/JCO.18.02463DOI Listing
April 2019

Sex as a predictor of response to cancer immunotherapy.

Lancet Oncol 2018 08;19(8):e376

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30483-2DOI Listing
August 2018

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Mol Cancer Res 2018 11 12;16(11):1724-1736. Epub 2018 Jul 12.

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-18-0171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214753PMC
November 2018

Role of Elevated Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.

Clin Cancer Res 2018 09 18;24(17):4119-4125. Epub 2018 May 18.

Center for Melanoma Research and Treatment, California Pacific Medical Center (CPMC) Research Institute, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-0791DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125189PMC
September 2018

Body-mass index and metastatic melanoma outcomes - Authors' reply.

Lancet Oncol 2018 05;19(5):e227-e228

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30266-3DOI Listing
May 2018

Estrogen returns to the stage in melanoma.

Pigment Cell Melanoma Res 2018 09 29;31(5):554-555. Epub 2018 Apr 29.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12706DOI Listing
September 2018

Melanoma brain metastases harboring BRAF or NRAS mutations are associated with an increased local failure rate following conventional therapy.

J Neurooncol 2018 Mar 2;137(1):67-75. Epub 2017 Dec 2.

Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 97, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2695-2DOI Listing
March 2018

Melanoma in 2017: Moving treatments earlier to move further forwards.

Nat Rev Clin Oncol 2018 02 28;15(2):75-76. Epub 2017 Nov 28.

Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.183DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436336PMC
February 2018

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

Melanoma Res 2017 12;27(6):545-557

aThe Hormel Institute, University of Minnesota, Austin, Minnesota bDepartment of Medicine and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Departments of cOncological Sciences dSurgery eDermatology fHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah gDepartment of Tumor Biology, Tumor Biology hDepartment of Cutaneous Oncology, Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida iDepartment of Medicine, Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital jDepartment of Global Health, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, DC kDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683096PMC
December 2017

Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.

Pigment Cell Melanoma Res 2018 01 2;31(1):11-30. Epub 2017 Nov 2.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12661DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742019PMC
January 2018

Primary medical therapy for BRAF-mutant melanoma brain metastases-is this good enough? - Authors' reply.

Lancet Oncol 2017 09;18(9):e509

Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30640-XDOI Listing
September 2017

Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes.

J Invest Dermatol 2017 08 23;137(8):1792-1795. Epub 2017 Apr 23.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2017.04.007DOI Listing
August 2017

Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma.

Clin Cancer Res 2017 Aug 7;23(16):4831-4842. Epub 2017 Apr 7.

Division of Molecular Oncology, Department of Translational Molecular Medicine, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559338PMC
August 2017

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Cancer Cell 2017 02;31(2):225-239

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.01.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501076PMC
February 2017

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Mol Cancer Ther 2017 03 30;16(3):516-528. Epub 2017 Jan 30.

Department of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-16-0552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337170PMC
March 2017

Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.

Cancer J 2017 Jan/Feb;23(1):68-74

From the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300745PMC
August 2017

Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors.

JAMA Dermatol 2017 Feb;153(2):228-229

Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2016.4068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484732PMC
February 2017

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.

Cancer Res 2016 09 3;76(18):5455-66. Epub 2016 Aug 3.

Department of Cancer Biology and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. Department of Cutaneous Biology and Dermatology, Thomas Jefferson University, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-3384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026598PMC
September 2016